This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Weber GF, Lett GS, Haubein NC. Osteopontin is a marker for cancer aggressiveness and patient survival. Br J Cancer 2010; 103: 861-9. doi: 10.1038/sj.bjc.6605834WeberGFLettGSHaubeinNCOsteopontin is a marker for cancer aggressiveness and patient survival2010103861910.1038/sj.bjc.6605834Open DOISearch in Google Scholar
Hao C, Cui Y, Owen S, Li W, Cheng S, Jiang WG. Human osteopontin: potential clinical applications in cancer (Review). Int J Mol Med 2017; 39: 1327-37. doi: 10.3892/ijmm.2017.2964HaoCCuiYOwenSLiWChengSJiangWGHuman osteopontin: potential clinical applications in cancer (Review)20173913273710.3892/ijmm.2017.2964Open DOISearch in Google Scholar
Wei R, Wong JPC, Kwok HF. Osteopontin - a promising biomarker for cancer therapy. J Cancer 2017; 8: 2173-83. doi: 10.7150/jca.20480WeiRWongJPCKwokHFOsteopontin - a promising biomarker for cancer therapy2017821738310.7150/jca.20480Open DOISearch in Google Scholar
Zhao H, Chen Q, Alam A, Cui J, Suen KC, Soo AP, et al. The role of osteopontin in the progression of solid organ tumour. Cell Death Dis 2018; 9: 356-70. doi: 10.1038/s41419-018-0391-6ZhaoHChenQAlamACuiJSuenKCSooAPThe role of osteopontin in the progression of solid organ tumour201893567010.1038/s41419-018-0391-6Open DOISearch in Google Scholar
Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. Jama-Journal Am Med Assoc 2002; 287: 1671-9. doi: 10.1001/jama.287.13.1671KimJHSkatesSJUedeTWongKKSchorgeJOFeltmateCMOsteopontin as a potential diagnostic biomarker for ovarian cancer20022871671910.1001/jama.287.13.1671Open DOISearch in Google Scholar
Cramer DW, Bast RC, Berg CD, Diamandis EP, Godwin AK, Hartge P, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res 2011; 4: 365-74. doi: 10.1158/1940-6207.CAPR-10-0195CramerDWBastRCBergCDDiamandisEPGodwinAKHartgePOvarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens201143657410.1158/1940-6207.CAPR-10-0195Open DOISearch in Google Scholar
Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T, et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A 2005; 102: 7677-82. doi: 10.1073/pnas.0502178102MorGVisintinILaiYZhaoHSchwartzPRutherfordTSerum protein markers for early detection of ovarian cancer200510276778210.1073/pnas.0502178102Open DOISearch in Google Scholar
Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008; 14: 1065-72. doi: 10.1158/1078-0432.CCR-07-1569VisintinIFengZLongtonGWardDCAlveroABLaiYDiagnostic markers for early detection of ovarian cancer20081410657210.1158/1078-0432.CCR-07-1569Open DOISearch in Google Scholar
Brakora KA, Lee H, Yusuf R, Sullivan L, Harris A, Colella T, et al. Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer. Gynecol Oncol 2004; 93: 361-5. doi: 10.1016/j.ygyno.2004.01.050BrakoraKALeeHYusufRSullivanLHarrisAColellaTUtility of osteopontin as a biomarker in recurrent epithelial ovarian cancer200493361510.1016/j.ygyno.2004.01.050Open DOISearch in Google Scholar
Schorge JO, Drake RD, Lee H, Skates SJ, Rajanbabu R, Miller DS, et al. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res 2004; 10: 3474-8. doi: 10.1158/1078-0432.CCR-03-0365SchorgeJODrakeRDLeeHSkatesSJRajanbabuRMillerDSOsteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer2004103474810.1158/1078-0432.CCR-03-0365Open DOISearch in Google Scholar
Lan Z, Fu D, Yu X, Xi M. Diagnostic values of osteopontin combined with CA125 for ovarian cancer: a meta-analysis. Fam Cancer 2016; 15: 221-30. doi: 10.1007/s10689-015-9847-3LanZFuDYuXXiMDiagnostic values of osteopontin combined with CA125 for ovarian cancer: a meta-analysis2016152213010.1007/s10689-015-9847-3Open DOISearch in Google Scholar
Hu Z-D, Wei T-T, Yang M, Ma N, Tang Q-Q, Qin B-D, et al. Diagnostic value of osteopontin in ovarian cancer: a meta-analysis and systematic review. PLoS One 2015; 10: e0126444. doi: 10.1371/journal.pone.0126444HuZ-DWeiT-TYangMMaNTangQ-QQinB-DDiagnostic value of osteopontin in ovarian cancer: a meta-analysis and systematic review201510e012644410.1371/journal.pone.0126444Open DOISearch in Google Scholar
Bao LH, Sakaguchi H, Fujimoto J, Tamaya T. Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers. J Biomed Sci 2007; 14: 373-81. doi: 10.1007/s11373-006-9143-1BaoLHSakaguchiHFujimotoJTamayaTOsteopontin in metastatic lesions as a prognostic marker in ovarian cancers2007143738110.1007/s11373-006-9143-1Open DOISearch in Google Scholar
Psyrri A, Kalogeras KT, Wirtz RM, Kouvatseas G, Karayannopoulou G, Goussia A, et al. Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group. J Transl Med 2017; 15: 1-11. doi: 10.1186/s12967-017-1134-7PsyrriAKalogerasKTWirtzRMKouvatseasGKarayannopoulouGGoussiaAAssociation of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group20171511110.1186/s12967-017-1134-7Open DOISearch in Google Scholar
Hacker NF. State of the art of surgery in advanced epithelial ovarian cancer. Ann Oncol 2013; 24: 27-32. doi: 10.1093/annonc/mdt465HackerNFState of the art of surgery in advanced epithelial ovarian cancer201324273210.1093/annonc/mdt465Open DOISearch in Google Scholar
Narod S. Can advanced-stage ovarian cancer be cured? Nat Rev Clin Oncol 2016; 13: 255-61. doi: 10.1038/nrclinonc.2015.224NarodSCan advanced-stage ovarian cancer be cured?2016132556110.1038/nrclinonc.2015.224Open DOISearch in Google Scholar
Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D, et al. European society of Gynaecological Oncology (ESGO) guidelines for ovarian cancer surgery. Int J Gynecol Cancer 2017; 27: 1534-42. doi: 10.1097/IGC.0000000000001041QuerleuDPlanchampFChivaLFotopoulouCBartonDCibulaDEuropean society of Gynaecological Oncology (ESGO) guidelines for ovarian cancer surgery20172715344210.1097/IGC.0000000000001041Open DOISearch in Google Scholar
Bristow RE, Karlan BY. Surgery for Ovarian Cancer: Principles and Practice 1st edition. Abingdon: Taylor & Francis; 2006.BristowREKarlanBYAbingdonTaylor & Francis2006Search in Google Scholar
Chesnais M, Lecuru F, Mimouni M, Ngo C, Fauconnier A, Huchon C. A preoperative predictive score to evaluate the feasibility of complete cytoreductive surgery in patients with epithelial ovarian cancer. PLoS One 2017; 12: 1-12. doi: 10.1371/journal.pone.0187245ChesnaisMLecuruFMimouniMNgoCFauconnierAHuchonCA preoperative predictive score to evaluate the feasibility of complete cytoreductive surgery in patients with epithelial ovarian cancer20171211210.1371/journal.pone.0187245Open DOISearch in Google Scholar
Gupta D, Lis CG. Role of CA125 in predicting ovarian cancer survival - A review of the epidemiological literature. J Ovarian Res 2009; 2: 1-20. doi: 10.1186/1757-2215-2-13GuptaDLisCGRole of CA125 in predicting ovarian cancer survival - A review of the epidemiological literature2009212010.1186/1757-2215-2-13Open DOISearch in Google Scholar
Kobal B, Jerman KG, Karo J, Verdenik I, Cerne K. Relationship of ovarian cancer tumour markers concentration between local fluid and serum: Comparison of malignant to benign condition. Eur J Gynaecol Oncol 2018; 5: 743-50. doi: 10.12892/ejgo3848.2018KobalBJermanKGKaroJVerdenikICerneKRelationship of ovarian cancer tumour markers concentration between local fluid and serum: Comparison of malignant to benign condition201857435010.12892/ejgo3848.2018Open DOISearch in Google Scholar
Jerman KG, Kobal B, Jakimovska M, Verdenik I, Cerne K. Control values of ovarian cancer tumor markers and standardisation of a protocol for sampling peritoneal fluid and performing washing during laparoscopy. World J Surg Oncol 2014; 12: 1-9. doi: 10.1186/1477-7819-12-278JermanKGKobalBJakimovskaMVerdenikICerneKControl values of ovarian cancer tumor markers and standardisation of a protocol for sampling peritoneal fluid and performing washing during laparoscopy2014121910.1186/1477-7819-12-278Open DOISearch in Google Scholar
Lutz AM, Willmann JK, Cochran F V., Ray P, Gambhir SS. Cancer screening: A mathematical model relating secreted blood biomarker levels to tumor sizes. PLoS Med 2008; 5: 1287-97. doi: 10.1371/journal.pmed.0050170LutzAMWillmannJKCochranF V.RayPGambhirSSCancer screening: A mathematical model relating secreted blood biomarker levels to tumor sizes2008512879710.1371/journal.pmed.0050170Open DOISearch in Google Scholar
Parsons SL, Watson SA, Steele RJ. Malignant ascites. Br J Surg 1996; 83: 6-14. doi: 10.1002/BJS.1800830104ParsonsSLWatsonSASteeleRJMalignant ascites19968361410.1002/BJS.1800830104Open DOISearch in Google Scholar
Stanojevic Z, Rancic G, Radic S, Potic-Zecevic N, Djordjevic B, Markovic M, et al. Pathogenesis of malignant ascites in ovarian cancer patients. Arch Oncol 2004; 12: 115-8. doi: 10.2298/AOO0402115SStanojevicZRancicGRadicSPotic-ZecevicNDjordjevicBMarkovicMPathogenesis of malignant ascites in ovarian cancer patients200412115810.2298/AOO0402115SOpen DOISearch in Google Scholar
Weber GF. The cancer biomarker osteopontin: Combination with other markers. Cancer Genomics Proteomics 2011; 8: 263-88. PMID: 22086896WeberGFThe cancer biomarker osteopontin: Combination with other markers2011826388PMID: 22086896Search in Google Scholar
Bandiera E, Zanotti L, Fabricio ASC, Bucca E, Squarcina E, Romani C, et al. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelinrelated peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis. Clin Chem Lab Med 2013; 51: 1815-24. doi: 10.1515/cclm-2013-0151BandieraEZanottiLFabricioASCBuccaESquarcinaERomaniCCancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelinrelated peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis20135118152410.1515/cclm-2013-0151Open DOISearch in Google Scholar
Sato S, Itamochi H. Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy. Ther Adv Med Oncol 2014; 6: 293-304. doi: 10.1177/1758834014544891SatoSItamochiHNeoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy2014629330410.1177/1758834014544891Open DOISearch in Google Scholar
Skof E, Merlo S, Pilko G, Kobal B. The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer. Radiol Oncol 2016; 50: 341-6. doi: 10.1515/raon-2016-0034SkofEMerloSPilkoGKobalBThe role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer201650341610.1515/raon-2016-0034Open DOISearch in Google Scholar
Rutten MJ, Leeflang MM, Kenter GG, Mol BW, Buist M. Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer. Cochrane Database Syst Rev 2014; 21. doi: 10.1002/14651858.CD009786. pub2RuttenMJLeeflangMMKenterGGMolBWBuistMLaparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer20142110.1002/14651858.CD009786Open DOISearch in Google Scholar
Cannistra SA. Cancer of the Ovary. N Engl J Med 1993; 329: 1550-9. doi: 10.1056/NEJM199311183292108CannistraSACancer of the Ovary19933291550910.1056/NEJM199311183292108Open DOISearch in Google Scholar
Bookman MA, Ozols RF. Factoring outcomes in ovarian cancer. J Clin Oncol 1996; 14: 325-7. doi: 10.1200/JCO.1996.14.2.325BookmanMAOzolsRFFactoring outcomes in ovarian cancer199614325710.1200/JCO.1996.14.2.325Open DOISearch in Google Scholar
Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist 2000; 5: 26-35. doi: 10.1634/theoncologist.5-1-26MarkmanMBookmanMASecond-line treatment of ovarian cancer20005263510.1634/theoncologist.5-1-26Open DOISearch in Google Scholar
Graessmann M, Berg B, Fuchs B, Klein A, Graessmann A. Chemotherapy resistance of mouse WAP-SVT/t breast cancer cells is mediated by osteopontin, inhibiting apoptosis downstream of caspase-3. Oncogene 2007; 26: 2840-50. doi: 10.1038/sj.onc.1210096GraessmannMBergBFuchsBKleinAGraessmannAChemotherapy resistance of mouse WAP-SVT/t breast cancer cells is mediated by osteopontin, inhibiting apoptosis downstream of caspase-320072628405010.1038/sj.onc.1210096Open DOISearch in Google Scholar
Hsieh I-S, Huang W-H, Liou H-C, Chuang W-J, Yang R-S, Fu W-M. Upregulation of drug transporter expression by osteopontin in prostate cancer cells. Mol Pharmacol 2013; 83: 968-77. doi: 10.1124/mol.112.082339HsiehI-SHuangW-HLiouH-CChuangW-JYangR-SFuW-MUpregulation of drug transporter expression by osteopontin in prostate cancer cells2013839687710.1124/mol.112.082339Open DOISearch in Google Scholar
Ng L, Wan T, Chow A, Iyer D, Man J, Chen G, et al. Osteopontin overexpression induced tumor progression and chemoresistance to oxaliplatin through induction of stem-like properties in human colorectal cancer. Stem Cells Int 2015; 2015: 1-8. doi: 10.1155/2015/247892NgLWanTChowAIyerDManJChenGOsteopontin overexpression induced tumor progression and chemoresistance to oxaliplatin through induction of stem-like properties in human colorectal cancer201520151810.1155/2015/247892Open DOISearch in Google Scholar
Zhang T, Zhang DM, Zhao D, Hou XM, Yang TN. Osteopontin expression is associated with platinum-based chemotherapy response and prognosis of patients with advanced non small cell lung cancer. J BUON 2014; 19: 742-8. PMID: 25261661ZhangTZhangDMZhaoDHouXMYangTNOsteopontin expression is associated with platinum-based chemotherapy response and prognosis of patients with advanced non small cell lung cancer2014197428PMID: 25261661Search in Google Scholar
Luo S-D, Chen Y-J, Liu C-T, Rau K-M, Chen Y-C, Tsai H-T, et al. Osteopontin involves cisplatin resistance and poor prognosis in oral squamous cell carcinoma. Biomed Res Int 2015; 2015: 1-13. doi: 10.1155/2015/508587LuoS-DChenY-JLiuC-TRauK-MChenY-CTsaiH-TOsteopontin involves cisplatin resistance and poor prognosis in oral squamous cell carcinoma2015201511310.1155/2015/508587Open DOISearch in Google Scholar
Faça VM, Ventura AP, Fitzgibbon MP, Pereira-Faça SR, Pitteri SJ, Green AE, et al. Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS One 2008; 3: e2425. doi: 10.1371/journal.pone.0002425FaçaVMVenturaAPFitzgibbonMPPereira-FaçaSRPitteriSJGreenAEProteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains20083e242510.1371/journal.pone.0002425Open DOISearch in Google Scholar